A Phase 1 interventional study of BI 1810631 - trial formulation 1 (TF1) and BI 1810631 - new formulation (NF) in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-04.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
BI 1810631 trial formulation 1 (TF1) is currently used in clinical trials, but is planned to be replaced by another formulation (principle) in future clinical trials and on the market. This trial intends to bridge pharmacokinetics (PK) between the two formulation principles. For this, relative bioavailability of TF1 and new formulation (NF) is assessed. Moreover the trial intends to inform on the effect of food and of the proton pump inhibitor rabeprazole on the PK of BI 1810631 after administration as NF in order to inform management of food and concomitant medications.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatments: R: TF1 fasted T1: NF fasted T2: NF fed T3: NF fasted + rabeprazole
Drug: BI 1810631 - trial formulation 1 (TF1) · Drug: BI 1810631 - new formulation (NF) · Drug: Rabeprazole sodium
Drug: BI 1810631 - trial formulation 1 (TF1) · Drug: BI 1810631 - new formulation (NF) · Drug: Rabeprazole sodium
Drug: BI 1810631 - trial formulation 1 (TF1) · Drug: BI 1810631 - new formulation (NF) · Drug: Rabeprazole sodium
Drug: BI 1810631 - trial formulation 1 (TF1) · Drug: BI 1810631 - new formulation (NF) · Drug: Rabeprazole sodium
BI 1810631 - trial formulation 1 (TF1)
Also known as: Zongertinib,, Hernexeos®
BI 1810631 - new formulation (NF)
Also known as: Zongertinib,, Hernexeos®
Rabeprazole sodium
Also known as: Pariet®
Area Under the Concentration-time Curve of BI 1810631 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
The area under the concentration-time curve of BI 1810631 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) was reported. Unit of geometric coefficient of variation (gCV) is %.
Time frame: Within 3 hours prior and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 34, 46, 70, 94 and 118 hours after BI 1810631 administration.
Maximum Measured Concentration of BI 1810631 in Plasma (Cmax)
The maximum measured concentration of BI 1810631 in plasma (Cmax) was reported. Unit of geometric coefficient of variation (gCV) is %.
Time frame: Within 3 hours prior and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 34, 46, 70, 94 and 118 hours after BI 1810631 administration.
Area Under the Concentration-time Curve of BI 1810631 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
The area under the concentration-time curve of BI 1810631 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) was reported. Unit of geometric coefficient of variation (gCV) is %.
Time frame: Within 3 hours prior and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 34, 46, 70, 94 and 118 hours after BI 1810631 administration.
This study was to investigate the relative bioavailability of 2 different BI 1810631 oral formulations (trial formulation 1 \[TF1\], Reference \[R\] and new formulation \[NF\], Test 1 \[T1\]) under fasting conditions; BI 1810631 NF under fasting (T1) and fed (T2) conditions; BI 1810631 NF given alone (T1) and together with the proton pump inhibitor rabeprazole (T3) under fasting conditions.
| Milestone | Treatment Sequence 1: R - T1 - T2 - T3 | Treatment Sequence 2: T1 - T3 - R - T2 | Treatment Sequence 3: T2 - R - T3 - T1 | Treatment Sequence 4: T3 - T2 - T1 - R |
|---|---|---|---|---|
| Started | 3 | 4 | 3 | 3 |
| Completed | 3 | 4 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1: R - T1 - T2 - T3 | Treatment Sequence 2: T1 - T3 - R - T2 | Treatment Sequence 3: T2 - R - T3 - T1 | Treatment Sequence 4: T3 - T2 - T1 - R |
|---|---|---|---|---|
| Started | 3 | 4 | 3 | 3 |
| Completed | 2 | 4 | 3 | 3 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Not attend visit | 1 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1: R - T1 - T2 - T3 | Treatment Sequence 2: T1 - T3 - R - T2 | Treatment Sequence 3: T2 - R - T3 - T1 | Treatment Sequence 4: T3 - T2 - T1 - R |
|---|---|---|---|---|
| Started | 2 | 4 | 3 | 3 |
| Completed | 2 | 4 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1: R - T1 - T2 - T3 | Treatment Sequence 2: T1 - T3 - R - T2 | Treatment Sequence 3: T2 - R - T3 - T1 | Treatment Sequence 4: T3 - T2 - T1 - R |
|---|---|---|---|---|
| Started | 2 | 4 | 3 | 3 |
| Completed | 1 | 4 | 3 | 3 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1: R - T1 - T2 - T3 | Treatment Sequence 2: T1 - T3 - R - T2 | Treatment Sequence 3: T2 - R - T3 - T1 | Treatment Sequence 4: T3 - T2 - T1 - R |
|---|---|---|---|---|
| Started | 1 | 4 | 3 | 3 |
| Completed | 1 | 4 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1: R - T1 - T2 - T3 | Treatment Sequence 2: T1 - T3 - R - T2 | Treatment Sequence 3: T2 - R - T3 - T1 | Treatment Sequence 4: T3 - T2 - T1 - R |
|---|---|---|---|---|
| Started | 1 | 4 | 3 | 3 |
| Completed | 1 | 2 | 3 | 2 |
| Not completed | 0 | 2 | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Not attend visit | 0 | 1 | 0 | 1 |
| Milestone | Treatment Sequence 1: R - T1 - T2 - T3 | Treatment Sequence 2: T1 - T3 - R - T2 | Treatment Sequence 3: T2 - R - T3 - T1 | Treatment Sequence 4: T3 - T2 - T1 - R |
|---|---|---|---|---|
| Started | 1 | 2 | 3 | 2 |
| Completed | 1 | 2 | 3 | 2 |
| Not completed | 0 | 0 | 0 | 0 |
The area under the concentration-time curve of BI 1810631 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) was reported. Unit of geometric coefficient of variation (gCV) is %.
| hour * nanomole / Liter (h*nmol/L) | TF1 Fasted (R) | NF Fasted (T1) | NF Fed (T2) | NF Fasted + Rabeprazole (T3) |
|---|---|---|---|---|
| Area Under the Concentration-time Curve of BI 1810631 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) | 4240 ± 52.7 | 5680 ± 18.8 | 4060 ± 13.7 | 5410 ± 27.6 |
The maximum measured concentration of BI 1810631 in plasma (Cmax) was reported. Unit of geometric coefficient of variation (gCV) is %.
| nanomole / Liter (nmol/L) | TF1 Fasted (R) | NF Fasted (T1) | NF Fed (T2) | NF Fasted + Rabeprazole (T3) |
|---|---|---|---|---|
| Maximum Measured Concentration of BI 1810631 in Plasma (Cmax) | 291 ± 93.1 | 399 ± 37.3 | 208 ± 31.4 | 327 ± 34.2 |
The area under the concentration-time curve of BI 1810631 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) was reported. Unit of geometric coefficient of variation (gCV) is %.
| hour * nanomole / Liter (h * nmol/L) | TF1 Fasted (R) | NF Fasted (T1) | NF Fed (T2) | NF Fasted + Rabeprazole (T3) |
|---|---|---|---|---|
| Area Under the Concentration-time Curve of BI 1810631 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) | 4550 ± 52.7 | 5980 ± 19.2 | 4310 ± 14.2 | 5660 ± 28.8 |
Collected over For R, T1, T2, and NF fasted + Rabeprazole (Rab.): From drug administration (admin.) till end of 14-day residual effect period (REP), up to 14 days. For Rab.: From drug admin. till end of REP of Rab., up to 8 days. All-cause mortality: From the first drug administration till end of trial, up to a total of 64 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TF1 Fasted (R) | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| NF Fasted (T1) | 0/12 (0%) | 0/12 (0%) | 1/12 (8.3%) |
| NF Fed (T2) | 0/9 (0%) | 0/9 (0%) | 4/9 (44.4%) |
| Rabeprazole | 0/11 (0%) | 0/11 (0%) | 2/11 (18.2%) |
| NF Fasted + Rabeprazole (T3) | 0/11 (0%) | 0/11 (0%) | 4/11 (36.4%) |
| Event | TF1 Fasted (R) | NF Fasted (T1) | NF Fed (T2) | Rabeprazole | NF Fasted + Rabeprazole (T3) |
|---|---|---|---|---|---|
| COVID-19Infections and infestations | 2/12 | 1/12 | 0/9 | 0/11 | 0/11 |
| HaemorrhoidsGastrointestinal disorders | 0/12 | 0/12 | 1/9 | 0/11 | 0/11 |
| NauseaGastrointestinal disorders | 0/12 | 0/12 | 1/9 | 0/11 | 0/11 |
| SunburnInjury, poisoning and procedural complications | 0/12 | 0/12 | 1/9 | 0/11 | 0/11 |
| RashSkin and subcutaneous tissue disorders | 0/12 | 0/12 | 1/9 | 0/11 | 0/11 |
| FuruncleInfections and infestations | 0/12 | 0/12 | 0/9 | 1/11 | 0/11 |
| HordeolumInfections and infestations | 0/12 | 0/12 | 0/9 | 1/11 | 0/11 |
| DiarrhoeaGastrointestinal disorders | 0/12 | 0/12 | 0/9 | 0/11 | 1/11 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/12 | 0/12 | 0/9 | 0/11 | 1/11 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/12 | 0/12 | 0/9 | 0/11 | 1/11 |
Treated set (TS): the TS included all subjects who were treated with at least one dose of trial drug.
| Age, Continuous(Years) | Treatment Sequence 1: R - T1 - T2 - T3 | Treatment Sequence 2: T1 - T3 - R - T2 | Treatment Sequence 3: T2 - R - T3 - T1 | Treatment Sequence 4: T3 - T2 - T1 - R | Total |
|---|---|---|---|---|---|
| Mean | 37.7 ± 7.0 | 33.5 ± 3.1 | 34.7 ± 8.5 | 34.0 ± 7.2 | 34.8 ± 5.8 |
| Sex: Female, Male(Participants) | Treatment Sequence 1: R - T1 - T2 - T3 | Treatment Sequence 2: T1 - T3 - R - T2 | Treatment Sequence 3: T2 - R - T3 - T1 | Treatment Sequence 4: T3 - T2 - T1 - R | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 3 | 4 | 3 | 3 | 13 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Sequence 1: R - T1 - T2 - T3 | Treatment Sequence 2: T1 - T3 - R - T2 | Treatment Sequence 3: T2 - R - T3 - T1 | Treatment Sequence 4: T3 - T2 - T1 - R | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 3 | 4 | 3 | 3 | 13 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Treatment Sequence 1: R - T1 - T2 - T3 | Treatment Sequence 2: T1 - T3 - R - T2 | Treatment Sequence 3: T2 - R - T3 - T1 | Treatment Sequence 4: T3 - T2 - T1 - R | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 0 | 1 |
| White | 3 | 3 | 3 | 3 | 12 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https:// www.mystudywindow.com/msw/datatransparency
Ran from Jun 2022 to primary completion in Sep 2022, 2 months.
Results were first posted in Nov 2025, 3 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rabeprazole